Stephen Hansen
Director of Biopharma Intelligence at BioCentury
Husband. Father of 2 exhausting boys. Director of Biopharma Intelligence @BioCentury. Lives → U.K., roots in Minnesota. Opinions my own. Landscape photography⬇⬇
Articles
-
1 week ago |
biocentury.com | Stephen Hansen
ARTICLE | Editor's CommentaryDespite the rumors, biotech’s specialist investors aren’t at crisis point By Stephen Hansen, Director of Biopharma IntelligenceRumors are flying about the precarious state of biotech’s specialist investor community. Let me set the record straight,the level of concern among investors is high, but theirsituation is not existential.
-
2 weeks ago |
biocentury.com | Stephen Hansen
DATA GRAPHICS | Data ByteSector leads broader market down as tariff worries persist By Stephen Hansen, Director of Biopharma IntelligenceFollowing a short reprieve on Wednesday, biotech indexes resumed their downward fall, leading the broader markets lower as investors continued to sell off equities amid concerns about President Donald Trump’s tariff policies, including the looming threat of pharma-specific tariffs.
-
2 weeks ago |
biocentury.com | Stephen Hansen
DATA GRAPHICS | Data ByteTwenty of the most active VCs raised more than $32.5B in last four years By Stephen Hansen, Director of Biopharma IntelligenceAn analysis of the most active VC investors over the past two years shows that despite biotech entering its second bear market within a five-year period, private life science investors still have plenty of dry powder to make new investments.
-
2 weeks ago |
zephyrnet.com | Stephen Hansen
How chaos at the U.S. regulator and a trade war are creating new uncertainties for biotech and investorsBy Stephen Hansen, Director of Biopharma IntelligenceApril 7, 2025 11:10 PM UTCLoss of leadership, cuts to staffing and a proposed reorganization at FDA have heightened biotech risk amid an already turbulent macroeconomic climate, according to BioCentury's Washington editor Steve Usdin.
-
2 weeks ago |
biocentury.com | Stephen Hansen
How chaos at the U.S. regulator and a trade war are creating new uncertainties for biotech and investors By Stephen Hansen, Director of Biopharma IntelligenceLoss of leadership, cuts to staffing and a proposed reorganization at FDA have heightened biotech risk amid an already turbulent macroeconomic climate, according to BioCentury’s Washington editor Steve Usdin.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 743
- Tweets
- 2K
- DMs Open
- No
RT @TheRock: My heart always skips a beat whenever I get the call from my friends at @MakeAWish letting me know we have a “Rush Wish” that…
RT @jeff_cranmer: "Not exactly a pick-me-up" says my @BioCentury pal @BioPharmaJosh about the new #BioCenturyThisWeek biotech podcast! But…
Latest from me on the #amylin #obesity deal: https://t.co/0mB0ezt8KZ
With the #Roche and #Zealand deal for up to $5.3B for #amylin agonist #petrelintide in #obesity, re-upping my story from last week on the promise of amylin in #obesity: https://t.co/3vrnvXFW8d $ROG $ZEAL $NVO $LLY $AZN $GUBRA $ABBV
